Evidera, Bethesda, MD
Firas Dabbous , Ching-Yu Wang , Daniel Simmons , Samuel Huse , Rami Jassim
Background: Data on the prevalence of emerging mutations /co-mutations (e.g., STK11, KRAS, and KEAP1) and associated clinical outcomes in metastatic non-small cell lung cancer (mNSCLC) patients are lacking therefore the objective of this study is to address these gaps in the current data. Methods: This study used the Flatiron clinico-genomic database and included newly diagnosed patients (≥18 years old) with stage IV NSCLC and known histology/PD-L1 status. Patients enrolled in clinical trials, with positive/missing EGFR or ALK, other malignancies, mixed histology, or without structured data within 90 days of diagnosis were excluded. The prevalence of STK11, KEAP1, KRAS mutations and co-mutations for each combination were evaluated in the overall study cohort and stratified by histology and PD-L1 status ( > or ≤1%). The overall survival (OS) from the date of diagnosis with stage IV was analyzed using Kaplan-Meier methods. Results: Of the 17,020 patients with NSCLC, 964 met the selection criteria and were included in the study. The prevalence of STK11, KEAP1, and KRAS is 18%, 15%, and 35%, respectively. With the exception of KRAS, the prevalence of all selected mutations and the co-mutations is higher in patients with PD-L1 negative and non-squamous NSCLC. The prevalence of KRAS is higher in patients with PD-L1 positive and non-squamous NSCLC (Table). The median OS was 10.1 months (95% CI, 8.6, 11.2) for the overall population, and 6.6 (5.7-8.3), 7.1 (5.8-8.8) and 9.9 (7.6-11.9) months in patients with STK11, KEAP1, and KRAS mutations, respectively. The median OS in patients with co-mutations ranges from 6.1 to 6.7 months. Conclusions: STK11, KEAP1, and KRAS mutations and co-mutations are common in mNSCLC patients. Current treatments, particularly in STK11, KEAP1, and co-mutation patients, are associated with poor OS. To address these harder to treat subgroups new treatment options or clinical trials should be considered.
Histology | PD-L1 | Analysis Type | N | STK11 | KEAP1 | KRAS | KRAS & STK11 | KRAS & KEAP1 | STK11 & KEAP1 | KRAS & STK11 & KEAP |
---|---|---|---|---|---|---|---|---|---|---|
Both | Both | OS (mutant vs wildtype) | 964 | 6.6 vs. 11.1 | 7.1 vs 10.7 | 9.9 vs 10.3* | 6.7 vs 10.8 | 6.4 vs 10.6 | 6.4 vs 11.3 | 6.1 vs 11.1 |
Prevalence† | 964 | 175 (18%) | 141 (15%) | 339 (35%) | 95 (10%) | 63 (7%) | 67 (7%) | 38 (4%) | ||
Squamous | Positive (> 1%) | Prevalence† | 164 | 5 (3%) | 13 (8%) | 21 (13%) | 0 (0%) | 4 (2%) | 3 (2%) | 0 (0%) |
Squamous | Negative (≤1%) | Prevalence† | 75 | 1 (1%) | 5 (7%) | 4 (5%) | 0 (0%) | 1 (1%) | 1 (1%) | 0 (0%) |
Non-squamous | Positive ( > 1%) | Prevalence† | 498 | 94 (19%) | 57 (11%) | 236 (47%) | 54 (11%) | 29 (6%) | 30 (6%) | 19 (4%) |
Non-squamous | Negative (≤1%) | Prevalence† | 227 | 75 (33%) | 66 (29%) | 78 (34%) | 41 (18%) | 29 (13%) | 33 (15%) | 19 (8%) |
OS= overall survival in months; †Prevalence is calculated among patients tested for each biomarker; *not statistically significant.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2023 ASCO Annual Meeting
First Author: Hina Khan
2023 ASCO Annual Meeting
First Author: Colin R Lindsay
2023 ASCO Annual Meeting
First Author: Petros Christopoulos
2023 ASCO Annual Meeting
First Author: Charu Aggarwal